Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

mor masses is a major unmet need in a wide range of settings. It is our belief that, as a result, this technology has the potential to provide a broadly active new modality to substantially improve patient outcomes in a variety of hard-to-treat tumor types. "

Phase III Study Design

The Phase III study design agreed with the FDA follows directly from the design of the previous study. The Phase III study will also enroll previously untreated patients with locally advanced disease. The primary objective of the study will be to demonstrate a statistically significant increase in 2-year event free survival (i.e. relapse, progression, or death) for patients treated with chemoradiation together with OncoVEX (GM-CSF) as compared to patients treated with chemoradiation alone. The study will involve approximately 400 patients with approximately 200 in each arm.

Phase I/II Study Design and Results

In a Phase I/II study, OncoVEX (GM-CSF) was administered by direct injection, at three dose levels, into tumor containing lymph nodes in combination with standard first line chemo radiotherapy every three weeks for four cycles. All patients then went for surgery. Of the 17 patients enrolled, 16 had Stage IV N2 or N3 disease. OncoVEX (GM-CSF) was shown to be well tolerated with no significant side effects in addition to those associated with chemoradiation. With respect to efficacy, 93% of patients had a complete pathological response at surgery, with five patients achieving a complete response after only 2 or 3 virus doses. No patient to date has had a loco-regional recurrence in the neck at a median follow up of 30 months, and the disease specific survival rate is currently 82%.

Dr Robert Coffin, Founder and Chief Technology Officer, for BioVex, said:

"Loco-regional control is extremely important in head and neck cancer where loco regional progr
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... YORK , May 16, 2013 ... new market research report is available ... MediPoint: Diagnostic Cardiac Biomarkers for Acute ... Market Forecasts http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Biomarkers for Acute Coronary Syndromes - ...
(Date:5/16/2013)... ON (PRWEB) May 16, 2013 DNA Genotek, ... announced ‘Spit for Africa’, a sponsorship program in conjunction with ... is designed to improve access and reduce the cost of ... projects such as the Human Heredity and Health in Africa ... the AfSHG. , The aim of the AfSHG ...
(Date:5/16/2013)... A number of residents in an apartment complex in ... abcactionnews.com, it was no thanks to the infestation of ... to the management and everyone else suffering from the pests ... public to try samples of it to prove it themselves ... 2013 determined that the complex invaded by bed ...
(Date:5/16/2013)... INTIO, Inc. is introducing ... cleared ClearStart SVM™ system at the World Congress of ... TipTRAC™, used in CT-guided ablative therapies, allows the physician ... needles relative to the outlines of the tumor selected ... EM navigation or by free hand. This “real time” ...
Breaking Biology Technology:MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 2Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 3INTIO Introduces TipTRAC™, its Newest Feature for its ClearStart SVM™ Intraoperative Imaging System 2
... VAP Cholesterol test can help doctors and clinicians identify ... options for patients at risk of heart disease, ... a,new cholesterol-fighting drug combination point to the need for ... other,lipids. That,s according to Atherotech, a cardio-diagnostic company that,has ...
... ABAX ), a medical products company manufacturing point-of-care,blood ... its,financial results for the third quarter of fiscal year ... 4:15 p.m. ET, Thursday, January 31, 2008., Participants ... the,conference call, or can listen via a live Internet ...
... ARIUS, Product Candidate Trop-2 Signal ... Transduction Antibody ... a full-,service biopharmaceutical development and protein production company, today,announced that ... Research, Inc., a biotechnology company focused on discovering,and developing the ...
Cached Biology Technology:Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3
(Date:5/17/2013)... New Jersey, and City University of New York have ... that effectively clears organisms to be viewed under microscopes. ... which is one of the few high-quality clearing solutions ... Drug Enforcement Administration (DEA) due to its use as ... vital for viewing organisms under a microscope. Without them, ...
(Date:5/17/2013)... College study finds human-caused climate change may have ... contradicting a host of recent studies that predict ... , The findings, which appear in the journal ... for survival of a creature thought to be ... tropical cold-blooded animals, especially forest lizards, will be ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... 2012 Researchers from Seattle Biomedical Research Institute (Seattle BioMed), ... uncovered new knowledge related to host-parasite interaction in severe malaria, ... in the brain and cause cerebral malaria the most ... published in the May 21 online edition of PNAS ( ...
... Darwin, assembling an evolutionary tree that shows the relationships between ... grandest and most daunting challenges facing biologists. Despite 150 ... no single diagram that displays the links between all of ... and microorganisms. Now, with $5.76 million from the U.S. ...
... build a grand tree of life that brings together everything ... the tiniest bacteria to the tallest tree. Scientists ... ever since Charles Darwin drew the first sketches in his ... branches of the tree of life, today there is still ...
Cached Biology News:New discoveries about severe malaria 2U-M biologist plays key role in effort to create first comprehensive tree of life 2U-M biologist plays key role in effort to create first comprehensive tree of life 3Researchers aim to assemble the tree of life for all 2 million named species 2Researchers aim to assemble the tree of life for all 2 million named species 3
Chemically Defined Lipid Concentrate...
...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Request Info...
Biology Products: